Further studies are required to explore if the repeated applications of BM-MSCs could prolong survival and delay the progression of ALS. Furthermore, our data indicate a temporary delay in the progression of ALS after a single combined IT and IV administration of BM-MSCs. Our study revealed that the concurrent IT and IV application of BM-MSCs in patients with ALS is a safe procedure. However, a significant reduction in ALSFRS-R and FVC levels was observed in these patients 6 months after BM-MSCs administration. The mean ALSFRS-R and FVC values remained stable during the first 3 months of the treatment. No serious adverse reaction was observed after combined IT and IV administration of BM-MSCs. To test this hypothesis, they recruited 189 patients with. The researchers hypothesized that if ALS patients were injected with these mesenchymal nerve stem cells, it could slow the progression of the ALS. Adverse reactions were assessed, and the clinical outcome was determined by the evaluation of the ALS functional rating scale-revised (ALSFRS-R) and forced vital capacity (FVC). The Steenblock Approach is a three week intensive program carried out in the doctors office and includes the use of stem cell rich bone marrow (aspirate) to. These nerve tissue stem cells have been shown to promote the production of molecules in the cerebral spinal fluid that protect nerve tissue. The cells can be injected into the muscle or the spinal canal. To assess the safety and efficacy, patients were examined at 1, 3, and 6 months following the treatment with BM-MSCs. Stem cell therapy in clinical trials for ALS BrainStorm Cell Therapeutics is developing NurOwn, an approach that uses mesenchymal stem cells that develop into cells that secrete neurotrophic factors. Fifteen patients were neurologically examined before BM-MSCs transplantation (1 × 10 6 cells/kg BW) to evaluate the rate of pre-treatment disease progression. Autologous BM-MSCs were isolated and expanded under standard conditions. This study was designed as a single-center, prospective, and open-label study without a placebo control group to assess the safety and efficacy of concurrent intrathecal (IT) and intravenous (IV) administration of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with ALS. Stem cell-based treatments have emerged as potentially effective approaches to delay the progression of amyotrophic lateral sclerosis (ALS).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |